Grimes, Pearl https://orcid.org/0000-0001-6663-2471
Hamzavi, Iltefat H. https://orcid.org/0000-0002-3137-5601
Bibeau, Kristen https://orcid.org/0000-0002-6871-2333
Harris, John E. https://orcid.org/0000-0002-7815-6430
van Geel, Nanja https://orcid.org/0000-0002-3249-8195
Parsad, Davinder https://orcid.org/0000-0003-0348-0815
Gardner, Jackie https://orcid.org/0000-0001-6923-7207
Valle, Yan https://orcid.org/0000-0002-9340-9045
Tlhong Matewa, Gaone https://orcid.org/0009-0002-4885-6054
Gao, Jessy https://orcid.org/0009-0003-9562-7497
Ren, Haobo https://orcid.org/0000-0002-4694-2795
Ezzedine, Khaled https://orcid.org/0000-0002-5468-4589
Funding for this research was provided by:
Incyte
Article History
Received: 2 January 2025
Accepted: 7 April 2025
First Online: 5 May 2025
Declarations
:
: Pearl Grimes has served as a consultant for Aclaris Therapeutics, Clarify Medical, DermaForce, Incyte Corporation, Proctor & Gamble, and Versicolor Technologies; and a principal investigator for Aclaris Therapeutics, Allergan/SkinMedica, Clinuvel Pharmaceuticals, Incyte, Johnson & Johnson, L’Oréal, Merz Pharma, Pfizer, Thync Global Inc., and VT Cosmetics. Iltefat H. Hamzavi has served as a consultant and investigator for AbbVie, Almirall, Avita, Boehringer Ingelheim, Galderma, Incyte, Janssen, Novartis, Pfizer, Sonoma, UCB, Union Therapeutics, and Vimela; immediate past president of the HS Foundation; and a board member of the Global Vitiligo Foundation. Kristen Bibeau was an employee and shareholder of Incyte at the time of the study. John E. Harris has served as a consultant for AbbVie, Aclaris Therapeutics, BiologicsMD, EMD Serono, Genzyme/Sanofi, Janssen, Pfizer, Rheos Medicines, Sun Pharmaceuticals, TeVido BioDevices, The Expert Institute, 3rd Rock Ventures, and Villaris Therapeutics; has served as an investigator for Aclaris Therapeutics, Celgene, Dermira, EMD Serono, Genzyme/Sanofi, Incyte, LEO Pharma, Pfizer, Rheos Medicines, Stiefel/GlaxoSmithKline, Sun Pharmaceuticals, TeVido BioDevices, and Villaris Therapeutics; holds equity in Aldena Therapeutics, NIRA Biosciences, Rheos Medicines, TeVido BioDevices, and Villaris Therapeutics; is a scientific founder of Aldena Therapeutics, NIRA Biosciences, and Villaris Therapeutics; and has patents pending for IL-15 blockade for treatment of vitiligo, JAK inhibition with light therapy for vitiligo, and CXCR3 antibody depletion for treatment of vitiligo. Nanja van Geel is a consultant and/or investigator for AbbVie, Bristol Myers Squibb, Idorsia Pharmaceuticals, Incyte Corporation, Merck/MSD, Pfizer, and Sun Pharma; and is Chair of the Vitiligo Task Force for the European Academy of Dermatology and Venereology (EADV). Davinder Parsad has served as an expert or primary investigator for Incyte, Pfizer, and Sun Pharmaceuticals. Jackie Gardner has served as a consultant for AbbVie, Avita Medical, Concert Pharmaceuticals, Incyte, Mitsubishi Tanabe Pharma Corporation, and Pfizer. Yan Valle is CEO of the Vitiligo Research Foundation, has served as a scientific advisor at Temprian Therapeutics, and as an invited professor at Guglielmo Marconi University. Gaone Tlhong Matewa is the founder of Beyond Vitiligo South Africa and cofounder of Beyond Vitiligo Botswana. Jessy Gao and Haobo Ren are employees and shareholders of Incyte. Khaled Ezzedine is a consultant for AbbVie, Incyte, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi, and Viela Bio.
: The study was performed in accordance with the Declaration of Helsinki and in adherence to the study protocol and local regulatory requirements. All survey participants provided informed consent at screening and could withdraw consent at any time. The study protocol received an exemption from the Western Institutional Review Board.